vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

The company’s cash position as of December 31, 2025, was $88.9M compared to $36.7M as of December 31, 2024. “In 2025, vTv delivered meaningful clinical and corporate progress that positions us for a highly productive 2026,” said Paul Sekhri, chairman, president and CEO of vTv Therapeutics (VTVT). “During the course of the year, we initiated patient dosing in the Phase 3 CATT1 trial evaluating cadisegliatin as an adjunct to insulin for the treatment of type 1 diabetes, strengthened our balance sheet with an $80.0 million financing with leading healthcare investors, and continued to expand our intellectual property estate supporting cadisegliatin. In early 2026, we secured an additional $20.0 million in non-dilutive funding.”